Veeva Systems (NYSE: VEEV) was a 7investing Best Buy three months in a row back in the summer of 2026, and the stock is up more than 77% since. Simon Erickson breaks down what made Veeva a buying opportunity when it fell 40% on news of its migration away from the Salesforce (NYSE: CRM) infrastructure it had relied on since 2007, including the valuation math (17x enterprise value to free cash flow), the customer retention data, and the $472 million in share buybacks that followed.Simon also explains why Veeva’s life sciences software platform has such strong staying power with big pharma customers like Pfizer (NYSE: PFE), Novartis (NYSE: NVS), and AstraZeneca (NASDAQ: AZN), and previews 7investing’s October 2026 Best Buys, announced the same day as this show.🔗 Free 7investing trial: https://7investing.com/subscribeThis is 7investing Live, streaming every Monday, Wednesday, and Friday at 10 AM ET, covering Best Buy breakdowns, stock recommendations, and long-term investing strategy.Stocks MentionedPublicly Traded:Veeva Systems, Inc. (NYSE:VEEV)Salesforce, Inc. (NYSE:CRM) AstraZeneca PLC (NASDAQ:AZN) Novartis AG (NYSE:NVS) Pfizer Inc. (NYSE:PFE) Bristol Myers Squibb Company (NYSE:BMY)ChaptersTime Chapter0:00 Welcome to 7investing Live1:41 Heather’s Excitement for Best Buys Day1:56 Veeva Systems’ Origin Story & Salesforce Partnership4:19 The Salesforce-Veeva “Schism” & Migration Announcement6:45 Veeva’s Valuation When It Became a Best Buy9:09 Veeva’s Strong 2026 Growth & Share Buybacks11:33 Why the Stock Dip Was a Short-Term Hiccup13:39 Q&A: Where Did Veeva’s Lost Customers Go?16:03 Peter Gassner’s Long-Term Vision as CEO18:15 Q&A: Can Veeva Attract New Customers?20:41 Wrap-Up & Best Buys Reveal Preview21:42 Next Show Preview: Lululemon Turnaround#7investing #SimonErickson #VeevaSystems #VEEVStock #BestBuy #StockMarket #SaaSStocks #LifeSciences #SalesforceStock #InvestingTips